GSK (LSE:GSK) is back in focus after presenting positive phase II data for its mRNA seasonal flu vaccine and confirming plans to start a phase III trial in September 2026, following Fast Track designation in the US.
Against this backdrop of pipeline news, GSK's share price has shown mixed short term momentum, with a 1-day share price return of 0.97% but a 30-day share price return that is down 3.11%, while the 1-year total shareholder return of 34.36% points to much stronger longer term performance as the market reassesses both growth prospects and risk around its portfolio.
Extend your research beyond GSK's latest trial news and take a closer look at other potential breakout candidates in our hand picked 6 healthcare AI stocks .
GSK now appears to be a stronger business story following its mRNA flu and oncology updates. The bigger challenge for investors comes next: do the current £18.72 share price and the recent 34% one-year return still leave enough value on the table?
Most Popular Narrative: 13.4% Undervalued
The most followed narrative for GSK puts fair value at £21.61, ahead of the £18.72 last close. This frames the current discount as meaningful but not extreme.
GSK is positioned to benefit from the global rise in demand for vaccines and specialty medicines, driven by an aging population and higher healthcare access in emerging markets, evidenced by ongoing growth in Shingrix, meningitis vaccines, and expansion in specialty medicines. This supports sustained revenue growth and greater resilience in future cash flows. Volume growth in key high-margin areas such as oncology (Jemperli, Blenrep), immunology (Benlysta, Nucala, depemokimab), and HIV (long-acting injectables) illustrates GSK's ability to capture premium pricing and leverage long-term trends toward therapies. This can affect future earnings and support margin expansion as these portfolios scale.
Want to see what sits behind that valuation gap? The narrative focuses on compounded revenue growth, rising margins and a tighter share count. It is worth examining how those ingredients combine into one long-term earnings path and a lower future P/E than many pharma peers.
Result: Fair Value of £21.61 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, GSK's story still faces pressure from potential patent expiries and ongoing legal cash outflows, both of which could weaken the current growth-led valuation case.
Next Steps
With GSK's mix of fresh trial news and ongoing legal and patent questions, it can be useful to examine the story yourself and act while sentiment is still forming. To weigh both sides in one place, review the 4 key rewards and 3 important warning signs .
Looking for more ideas beyond GSK?
If you only stop at GSK, you risk missing other opportunities that fit your style. Use the Simply Wall Street Screener to line up your next candidates.
-
Target income resilience by reviewing companies we flag as potential 3 dividend fortresses that may suit investors who prioritise cash returns.
-
Hunt for mispriced quality and scan our 8 high quality undiscovered gems that highlight companies with strong fundamentals that fewer investors currently follow.
-
Prioritise capital preservation and focus on the 6 resilient stocks with low risk scores that concentrates on businesses with more resilient risk profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GSK.L .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
